Archives: Questions And Answers
A bit of a morbid question, sorry. Is it possible to model an escalating number of (non-fatal) casualties on CSL’s revenue? Would an extra 10,000 wounded in a month move the needle?
I’d value your opinion on Bapcor, which has had a rough time and is offering shareholders shares at $0.60 each. Should we chase the loss and not get diluted? It seems like we have little choice but to buy and hope, sitting on such a large loss from $5.20 only a year ago!
Thanks, Campbell.
I’m looking to park cash while not trading. How does MMKT shape up as a safe place to do so? It pays around 5%+ pa, paid monthly. Cheers
I have a small holding in 4DX. Taking a few pertinent points from their 19th Jan investor presentation it is easy to understand the perceived value:-
CT:VQ product has FDA approval and has reimbursement code for hospitals. The market in the US alone deemed north of $1b annually. The patented imaging software runs on all existing CT scanners so hospitals do not need to buy new or extra hardware. Phillips saleforce contracted to push hard on hospital adoptions
And the clincher to me is that their competition requires each patient to inhale a low dose of nuclear contrast material to enable lung performance imaging.
All great positives leading to their claim of obtaining a ‘mere’ 100% of the US market in a short period of time.
Hi MM,
Hi Guys